PT-141 (Bremelanotide/Vyleesi) Primary uses: Female sexual dysfunction (FDA-approved) Male erectile dysfunction Libido enhancement for both sexes Typical dosing: 1-2mg, 45-90 minutes before sexual activity Use as needed (not daily) Administration: Subcutaneous injection Special notes: Works through CNS (brain), not vascular system FDA-approved for female sexual dysfunction Effective for both men and women Side effects: nausea (common but temporary), flushing Melanotan II Primary uses: Tanning (primary) Libido enhancement (secondary) Appetite suppression Typical dosing: 0.5-1mg, 2-3 times per week Duration: Ongoing for tanning maintenance Administration: Subcutaneous injection Special notes: Causes significant skin darkening (permanent) Increases libido as side effect Nausea common initially Safety concerns about long-term use Kisspeptin Primary uses: Natural testosterone support Fertility enhancement Libido increase Typical dosing: 1-2mg, 2-3 times per week Duration: Ongoing for hormonal support Administration: Subcutaneous injection Special notes: Stimulates GnRH (gonadotropin-releasing hormone) Can increase natural testosterone 15-30% Useful for fertility issues Research-stage peptide See our peptides for men guide for male sexual health protocols

Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P (2007) Toll-like receptor 3 expressed by melanoma cells as a target for therapy
If someone has type 2 diabetes and/or obesity, however, their naturally occurring GLP-1 may not be as robust
Cost-effectiveness of obesity treatments: glucagon-like peptide-1 receptor agonists, endoscopic sleeve gastroplasty, and metabolic/bariatric surgery
Tirzepatide adds a GIP receptor agonist mechanism that semaglutide lacks, which may reactivate weight loss in some patients
Only tirzepatide was associated with a greater proportion of patients achieving at least 25% TBWL reduction (odds ratio [95% confidence interval]: 33.8 [18.461.9], P 10%)